Medical management for benign prostatic hyperplasia

Research output: Contribution to journalReview article

5 Citations (Scopus)

Abstract

The aim of therapy for benign prostatic hyperplasia. (BPH) is to improve quality of life by providing symptom relief and an increased maximum flow rate, as well as reduce disease progression and the development of new morbidities. There has been an enormous decline in the popularity of surgery and it is now apparent that medication is the most frequently used treatment for BPH. This has arguably therefore been the most major change in urological clinical practice in the last decade. Currently α1-adrenoceptor antagonists are the commonest medical therapy, and are thought to act by relaxing prostatic smooth muscle, the neural or so-called 'dynamic' component of BPO. 5 α-reductase inhibitors are another option for BPH, which reduce prostatic mass and therefore the mechanical or 'static' component of benign prostatic obstruction (BPO). Another group of agents are the phytotherapeutic extracts, which act via various mechanisms, many as yet poorly defined. This review critically assesses existing publications relating to the medical management of BPH.

Original languageEnglish
Pages (from-to)233-243
Number of pages11
JournalKorean Journal of Urology
Volume48
Issue number3
DOIs
Publication statusPublished - 2007 Jan 1

Fingerprint

Prostatic Hyperplasia
Adrenergic Receptors
Smooth Muscle
Disease Progression
Publications
Oxidoreductases
Quality of Life
Morbidity
Therapeutics

All Science Journal Classification (ASJC) codes

  • Urology

Cite this

@article{cc9f9a1e855d495fa7d1d7e421932ef2,
title = "Medical management for benign prostatic hyperplasia",
abstract = "The aim of therapy for benign prostatic hyperplasia. (BPH) is to improve quality of life by providing symptom relief and an increased maximum flow rate, as well as reduce disease progression and the development of new morbidities. There has been an enormous decline in the popularity of surgery and it is now apparent that medication is the most frequently used treatment for BPH. This has arguably therefore been the most major change in urological clinical practice in the last decade. Currently α1-adrenoceptor antagonists are the commonest medical therapy, and are thought to act by relaxing prostatic smooth muscle, the neural or so-called 'dynamic' component of BPO. 5 α-reductase inhibitors are another option for BPH, which reduce prostatic mass and therefore the mechanical or 'static' component of benign prostatic obstruction (BPO). Another group of agents are the phytotherapeutic extracts, which act via various mechanisms, many as yet poorly defined. This review critically assesses existing publications relating to the medical management of BPH.",
author = "Byungha Chung",
year = "2007",
month = "1",
day = "1",
doi = "10.4111/kju.2007.48.3.233",
language = "English",
volume = "48",
pages = "233--243",
journal = "Korean Journal of Urology",
issn = "2005-6737",
publisher = "Korean Urological Association",
number = "3",

}

Medical management for benign prostatic hyperplasia. / Chung, Byungha.

In: Korean Journal of Urology, Vol. 48, No. 3, 01.01.2007, p. 233-243.

Research output: Contribution to journalReview article

TY - JOUR

T1 - Medical management for benign prostatic hyperplasia

AU - Chung, Byungha

PY - 2007/1/1

Y1 - 2007/1/1

N2 - The aim of therapy for benign prostatic hyperplasia. (BPH) is to improve quality of life by providing symptom relief and an increased maximum flow rate, as well as reduce disease progression and the development of new morbidities. There has been an enormous decline in the popularity of surgery and it is now apparent that medication is the most frequently used treatment for BPH. This has arguably therefore been the most major change in urological clinical practice in the last decade. Currently α1-adrenoceptor antagonists are the commonest medical therapy, and are thought to act by relaxing prostatic smooth muscle, the neural or so-called 'dynamic' component of BPO. 5 α-reductase inhibitors are another option for BPH, which reduce prostatic mass and therefore the mechanical or 'static' component of benign prostatic obstruction (BPO). Another group of agents are the phytotherapeutic extracts, which act via various mechanisms, many as yet poorly defined. This review critically assesses existing publications relating to the medical management of BPH.

AB - The aim of therapy for benign prostatic hyperplasia. (BPH) is to improve quality of life by providing symptom relief and an increased maximum flow rate, as well as reduce disease progression and the development of new morbidities. There has been an enormous decline in the popularity of surgery and it is now apparent that medication is the most frequently used treatment for BPH. This has arguably therefore been the most major change in urological clinical practice in the last decade. Currently α1-adrenoceptor antagonists are the commonest medical therapy, and are thought to act by relaxing prostatic smooth muscle, the neural or so-called 'dynamic' component of BPO. 5 α-reductase inhibitors are another option for BPH, which reduce prostatic mass and therefore the mechanical or 'static' component of benign prostatic obstruction (BPO). Another group of agents are the phytotherapeutic extracts, which act via various mechanisms, many as yet poorly defined. This review critically assesses existing publications relating to the medical management of BPH.

UR - http://www.scopus.com/inward/record.url?scp=34347251564&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34347251564&partnerID=8YFLogxK

U2 - 10.4111/kju.2007.48.3.233

DO - 10.4111/kju.2007.48.3.233

M3 - Review article

VL - 48

SP - 233

EP - 243

JO - Korean Journal of Urology

JF - Korean Journal of Urology

SN - 2005-6737

IS - 3

ER -